Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

BACKGROUND: Capecitabine plus oxaliplatin (XELOX) has been established as a first-line treatment for metastatic colorectal cancer. Adherence is particularly important with capecitabine to maintain appropriate curative effect. In this study, we monitored the adherence to capecitabine on XELOX treatme...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Patient Prefer Adherence
Glavni autori: Kawakami, Kazuyoshi, Nakamoto, Eri, Yokokawa, Takashi, Sugita, Kazuo, Mae, Yutarou, Hagino, Akane, Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Oniyama, Sayaka, Machida, Yoshiaki, Yamaguchi, Toshiharu, Hama, Toshihiro
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2015
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4399552/
https://ncbi.nlm.nih.gov/pubmed/25914526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S80327
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items